Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

3(42.9%)

7Total

Phase 1(4)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07454915Phase 2Recruiting

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Role: lead

NCT05743595Phase 1Active Not Recruiting

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Role: collaborator

NCT04713046Phase 1Active Not Recruiting

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

Role: collaborator

NCT06210854Phase 2Not Yet Recruiting

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Role: collaborator

NCT06508138Phase 1Enrolling By Invitation

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

Role: collaborator

NCT02405221Phase 1Completed

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer

Role: collaborator

NCT03911076Phase 2Terminated

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

Role: lead

All 7 trials loaded